This workbook contains the current version of the Global Health EDCTP3's **Monitoring & Evaluation (M&E) framework,** which aims to establish a systematic and structured approach to tracking Programme results across all stages of its lifecycle, providing evidence to support timely adjustments in its activity plans and strategic decision-making.

The current Framework has been developed through document analysis and targeted consultations with Global Health EDCTP3 staff, EDCTP Association colleagues, and with input from the Global Health EDCTP3 Stakeholder Group, Scientific Committee, and Governing Board.

The Framework is intended to serve as a **living tool - flexible and adaptable - to be refined over time** as Programme implementation advances, global health priorities evolve, and practical insights emerge. Adjustments may be needed based on the actual effort required to measure certain KPIs, the resources available and the data realities in specific contexts - factors that will only become fully clear when measurement of specific indicators is being done.

The Framework includes the following components:

1. Programme Logic - The foundation of the M&E Framework, outlining the specific public health improvements to which the Programme seeks to contribute, and the pathway through which it aims to trigger those improvements. The Programme logic summarises the expected causal chain of Programme results, illustrating how **resources** and **activities** are expected to generate specific deliverables - **outputs**, how these outputs are expected to lead to immediate effects - immediate **outcomes**, and how these, in turn, are anticipated to contribute to broader, longer-term changes - **intermediate, long-term outcomes and impact**.

2. All Indicators (KPIs) - A comprehensive list of KPIs aligned with the Programme logic, covering all levels from activities to outputs, outcomes and impact. KPIs are designed to provide information on the extent to which specific activities have been implemented and whether the intended results at the output, outcome and impact levels have been achieved. The presentation of KPIs includes:

- **Column A**: Exact wording of specific activities and results from the Programme logic (color-coded to match the Programme logic diagram).
- **Column C**: Corresponding proposed KPIs (also color-coded for alignment with the Programme logic diagram).
- **Additional columns:** Detailing disaggregation dimensions, KPI type (donor-mandated or EDCTP-specific), proposed data collection frequency, and suggested methods and sources. These elements form the basis for the M&E implementation plan.

3. Core KPIs - A selection of up to 25 key KPIs providing a high-level snapshot of the Programme's performance. These are drawn from the full list, ensuring alignment with Global Health EDCTP3's objectives.

4. Summaries - A list of tables clustering KPIs by category, level of difficulty for data collection, etc.

Donor-mandated KPIs: There are three types, as marked in column F in '2. All Indicators' sheet:
- Horizon Programme indicators (KIPs): Measured directly by the Horizon Programme and data provided to the Global Health EDCTP3 team upon request.
- Joint Undertaking (JU) Common KPIs: Shared across all JUs.
- EC Reporting Requirements: Data required for reporting under the Regulation 2021/2085 ('Single Basic Act').

Additionally, **Global Health EDCTP3-specific KPIs** have been included to track results unique to the Programme that are not (sufficiently) covered by the donor-mandated ones.

Global Health EDCTP3 Joint Undertaking (JU)- Programme Logic

RESULTS – 'PATHWAY TO IMPACT'

| ISSUES | INPUTS / ACTIVITIES | → OUTPUTS | → OUTCOMES (immediate → intermediate → long-term) | → IMPACT |

ISSUES

- negative impact of infectious diseases on individuals, economy & society
- infectious diseases kill, cause disabilities, reduce quality of life & productivity
- outbreaks in SSA threaten European & global health security
- **high morbi-mortality by infectious diseases in SSA**
- limited preparedness & resilience of health systems for timely & effective response to epidemic outbreaks
- limited technologies for tackling infectious diseases affecting SSA
- limited workforce capacity to develop, implement & regulate technologies for tackling infectious diseases
- limited technical capacity (physical, processes) for clinical research
- insufficient ethics & regulatory environment for clinical research
- limited & fragmented investment & collaborations for tackling infectious diseases
- insufficient alignment among stakeholders for tackling infectious diseases

INPUTS / ACTIVITIES

- **a1. ensure** efficient & effective **operational management** of the JU to support programme implementation
- **a2. coordinate** activities of the JU **governing & advisory bodies** & ensure information flow between them & programme office team
- **a3. establish annual funding priorities** with inputs from governing & advisory bodies, EDCTP Association members & partners
- **a4. raise awareness** among relevant stakeholders about JU's objectives, results, priorities & grant opportunities
- **a5. launch grant calls**, evaluate proposals & select grantees for clinical research, capacity building, networking & epidemic response
- **a6. fund RIA & CSA projects** & monitor their implementation for progress, compliance, & quality standards
- **a7. provide guidance** to JU grantees & other clinical research implementors on implementation of clinical research projects
- **a8. monitor** & collate **IKAA contributions** to EDCTP objectives
- **a9. foster** North-North, North-South, & South-South **networking & collaborations** in global health & efforts tackling infectious diseases
- **a10. promote** the use of **EDCTP-supported networking platforms** for dialogue & collaborations between grant applicants, grantees & other stakeholders
- **a11. monitor priorities & strategies** of key global, regional & national stakeholders on infectious diseases in SSA

→ OUTPUTS

health technologies
- **op1. new knowledge** on new/ improved health technologies for the management of infectious diseases in SSA is **produced & communicated** to the public & to relevant stakeholders
- **op2. exploitation** of new/ improved technologies is **planned** under reasonable conditions or non-exclusive licenses, with due attention to market exploration & IP when relevant
- **op3. stakeholders & communities** in participating countries, incl. industry & SMEs, are **appropriately engaged** in all stages of the JU-supported projects

research capacity
- **op4. enhanced institutional & technical capacity** of organisations involved in the JU-supported projects to tackle infectious diseases, incl. upgraded laboratories & clinical facilities
- **op5. set/ strengthened functional ethics & regulatory frameworks** in project countries, based on international standards for GCP
- **op6. individuals in SSA**, including underrepresented groups, develop experience & complete **training, mentoring & coaching** in clinical research implementation, oversight & governance

partnerships & collaborations
- **op7. increased visibility** of the JU & its strategic priorities among relevant stakeholders in global health research & policy
- **op8. broadened & more inclusive engagement** of **countries & strategic actors** in the JU governance, joint calls & policy-level initiatives
- **op9. increased co-funding** mobilised by the JU from external stakeholders for research & capacity development on infectious diseases
- **op10. increased & more inclusive collaboration** among SSA & European **organisations, researchers**, industry, SMEs, investors & external **experts** engaged in the JU-supported projects & processes

→ OUTCOMES

- **oc6.** the **new knowledge** created through EDCTP grants **advances the medical field & clinical practice** for tackling infectious diseases
- **oc7.** new/ improved technologies are **approved for use** & included in relevant **protocols, policies & guidelines**
- **oc8.** new/ improved technologies are **available, accessible, affordable, & accepted** for use by intended end beneficiaries
- **oc9. strengthened clinical research institutions in SSA**, with improved equipment, job opportunities, internal processes & market share
- **oc10. increased maturity** of national **regulatory & ethics systems** for health product development, enabling sustainable oversight beyond the JU support
- **oc11. upskilled individuals** become **more effective** in producing and disseminating **knowledge & practice** on tackling infectious diseases in SSA
- **oc12. better alignment** across Europe & Africa on a **global health research agenda** & better coordinated regional & national research programs on infectious diseases
- **oc13. better aligned regulatory mechanisms** & increased **common regulatory reviews** in SSA for new health products
- **oc14. increased co-funding & joint activities** across sectors to **develop, exploit** or **scale up** EDCTP-supported new/ improved health technologies

- **oc1.** new/ improved **technologies are used** for diagnosing, treating & preventing infectious diseases in SSA
- **oc2. strengthened R&I capacities & national health systems** in SSA for tackling infectious diseases
- **oc3. improved capacity** of SSA institutions to detect & diagnose **emerging diseases** of epidemic potential
- **oc4. improved efficiency & effectiveness** of public & private **investments** in combatting infectious diseases in SSA
- **oc5. strengthened North-North, North-South & South-South partnerships** in global health research among private & public sector organisations

→ IMPACT

- **Im1.** reduced socio-economic burden of infectious diseases in SSA
- **Im2.** increased health security in SSA & globally, including with regards to AMR & effects of climate change
- **Im3.** progress towards SDGs, EU & AU policy priorities

KPIs:
- ★ KPIs: Core
- ● KPIs: donor-mandated
- ● KPIs: specific to EDCTP

TARGET GROUPS: (1) patients & communities affected by infectious diseases in SSA, with particular focus on populations with major unmet medical needs; (2) healthy communities in EU, SSA & globally; (3) health researchers, institutional health stakeholders in SSA & EU; (4) product developers.
TARGET TECHNOLOGIES: treatment, diagnostics, prevention, prognostics, digital/ AI

Global Health EDCTP3 Joint Understaking (JU) - M&E Framework, list of indicators

JU mention below refers to Global Health EDCTP3

Programme Activities & Results same as in Programme Logic		Indicators information that shows the extent to which activities have been implemented or results have been achieved **green: core KPIs (max 25)**	Indicator definitions / calculation mode	disagregates, by: black: EDCTP-specific; red: donor-mandated	indicator type black: EDCTP specific; red: donor-mandated	effort required for data collection (low/moderate/high)	data collection frequency	sources & methods of data collection (means of verification)
INPUTS/ ACTIVITIES								
a1. ensure efficient & effective **operational management** of the JU to support programme implementation	i1	**HR - occupancy rate**	% staff positions filled and operational within the organization, counting both statutory and interim (numerator: # fte-equivalent filled; denominator: #fte-equivalent planned)		EC Reporting Requirements	low	yearly	JU internal records
	i2	**JU budget implementation and execution:** *- commitment (CA) to total budget* *- payments (PA) to total budget*			EC Reporting Requirements	low	yearly	JU internal records on payments
	i3	**payments made on time** *for grants and all other types of payments* *# and %*		• type of payment (administrative, grants)	EC Reporting Requirements	low	yearly	JU internal records on payments
	i4	**average # days for Time-to-Inform (TTI), and Time-to-Grant (TTG), for grant proposals submitted for Global Health EDCTP3 funding**	TTG: # days between the application deadline and the date the grant agreement is signed, for granted projects TTI: # days between the application deadline and the date candidates are informed of the selection outcomes, for all proposals	• call • type (TTI, TTG)	EC Reporting Requirements	low	after each call selection completion	Corda Horizon Europe dashboard
	i5	**proposals/ grants for which TTI, TTG, TTP were within established limits** *# and %*	numerator: # proposals with timely TTI (for all proposals) and TTG (for granted projects); denominator: total # proposals (TTI) and projects under GAP (TTG)	• call • type (TTI, TTG, TTP)	EC Reporting Requirements	low	after each call selection completion	Corda Horizon Europe dashboard
a2. coordinate activities the JU **governing & advisory bodies** & ensure information flow between them and programme office team	i6	**# annual meetings of Global Health EDCTP3 governing & advisory bodies**		• governing / advisory body	EC Reporting Requirements	low	yearly	JU internal records
	i7	**# decisions/ written procedures adopted by Global Health EDCTP3 governing board**		• decision type • governing / advisory body	EC Reporting Requirements	low	yearly	JU internal records
a3. establish annual funding priorities with inputs from governing and advisory bodies, EDCTP association members & partners			*not tracked with KPI, but action described in Annual Activity Report to EC*					
a4. raise awareness among relevant stakeholders about Global Health EDCTP3 objectives, results, priorities & grant opportunities	i8	**# events where presentation about Global Health EDCTP3 was included in the agenda**		• type of event • audience size • audience geographic scope	EDCTP-specific	low	yearly	• JU internal records • data to be compiled based on dedicated template
	i9	**# impressions and views of Global Health EDCTP3 posts through online media**		• type of reach • type of media • country & world region	EDCTP-specific	low	monthly	• online media analytics reports • Communications internal dashboard
	i10	**# subscribers/followers to Global Health EDCTP3 social media outlets (incl newsletter)**		• outlet • country & world region	EDCTP-specific	low	monthly	online media analytics reports
	i11	**# visitors of Global Health EDCTP3 stands with whom there was interraction (conversations, demos given, questions answered) at public events**		• event type • interraction type	EDCTP-specific	low	after each event with JU stand	• JU internal records • data to be compiled based on dedicated template
	i12	**# public grant portals with which Global Health EDCTP3 shares data on funding of clinical research**		• theme • geographic coverage	EDCTP-specific	low	yearly	JU internal records
	i13	**# calls & call topics for grant proposals launched**		• call & call topic	EC Reporting Requirements	low	after each call launch	• Corda • Horizon Europe dashboard

Activity	ID	Indicator	Definition / Note	Breakdown	Reporting Requirement	Priority	Frequency	Data Source
a5. launch grant calls, evaluate proposals & select grantees for clinical research, capacity building, networking & epidemic response	i14	# proposals submitted	# proposals submitted before admissibility & eligibility check	• call & call topic • participants' type (incl SMEs and PDPs) • participants' newcomer status • country / world region • by eligibility and adminissibility status	EC Reporting Requirements	moderate	after each call deadline	• Corda • Horizon Europe dashboard • Internal spreadsheet for beneficiary newcomer status
	i15	average evaluation scores of proposals		• call & call topic • placement below/above quality threshold	EC Reporting Requirements	low	after each call selection completion	• Corda • SEP
	i16	success rate - % proposals retained	denominator: # full and eligible proposals	• call & call topic	EC Reporting Requirements	low	after each call selection completion	• Corda • Internal spreadsheet for renewal status analysis • Census based- internal spreadsheet for grants' categorisation by disease, technology, research type, trial phase, target groups • Internal records of EDCTP Association
	i17	# projects selected for funding, with signed Grant Agreements		• call & call topic • participants' newcomer status • participants' type (incl SMEs and PDPs) • disease; technology; research type (including research of cost effectiveness and economic benefits of research products; research on uptake of results into policy and practice); trial phase; target groups (including vulnerable populations groups specified in SRIA) • country • EDCTP iteration • completion status	EC Reporting Requirements	moderate	quarterly	• Corda • Internal spreadsheet for renewal status analysis • Census based- internal spreadsheet for grants' categorisation by disease, technology, research type, trial phase, target groups • Internal records of EDCTP Association
a6. fund RIA and CSA grants & monitor their implementation for progress, compliance, and quality standards	i18	grant amounts allocated to projects (EUR), committed and actual		• call & call topic • participants' type (incl SMEs and PDPs) • disease; technology; research type (including research of cost effectiveness and economic benefits of research products; research on uptake of results into policy and practice); trial phase; target groups (including vulnerable populations groups specified in SRIA) • country • EDCTP iteration • committed vs actual	EC Reporting Requirements	low	quarterly	• Corda • JU internal records on payments • Census based- internal spreadsheet for grants' categorisation by disease, technology, research type, trial phase, target groups • Internal records of EDCTP Association
	i19	% periodic reports submitted and approved within time limits		• call • type of action • submitted on time or not • approved on time or not	EDCTP-specific	low	yearly	• Corda • JU internal records on REPAs
	i20	residual error rate	proportion of errors remaining after corrective and preventive actions have been applied	• call • country	EC Reporting Requirements	low	yearly	Audit reports
a7. provide guidance to JU grantees & other clinical research implementors on implementation of clinical research projects	i21	# finance & project management trainings organised for beneficiaries of Global Health EDCTP3 funded projects		• delivery location	EDCTP-specific	low	yearly	• Reports from EDCTP South Africa Office • data to be compiled based on dedicated template
	i22	# unique participants in finance & project management trainings organised for beneficiaries of Global Health EDCTP3 funded projects	"Unique" = individuals participating in several trainings counted once	• gender • main nationality • role type in respective projects • project	EDCTP-specific	low	yearly	• Reports from EDCTP South Africa Office • data to be compiled based on dedicated template
	i23	# and % Global Health EDCTP3-funded projects whose team members attended finance & project management trainings organised for Global Health EDCTP3 funded projects		• project type	EDCTP-specific	low	yearly	• Reports from EDCTP South Africa Office • Corda
	i24	# unique views / # downloads of webpages of data management and data sharing toolkits on EDCTP knowledge hub		• country / world region • toolkit type	EDCTP-specific	low	yearly	• Analytics reports from EDCTP knowledge hub online platform
a8. monitor & collate **IKAA contributions** to EDCTP3 objectives			*not tracked with KPI, but action to be described in AARs contributions by IKAAs captured through indicators for op7*					
a9. foster North-North, North-South, & South-South **networking & collaborations** in global health & efforts tackling infectious diseases	i25	# stakeholders with which Global Health EDCTP3 held discussions about potential collaboration / to maintain existing collaboration		• outcome • type of collaboration • stakeholder's sector • new/ongoing collaboration	EDCTP-specific	low	yearly	• internal records / dedicated template

a10. promote the use of **EDCTP-supported networking platforms** for dialogue & collaborations between grant applicants, grantees & other stakeholders			*not tracked with KPI, but action to be described in AARs*					
a11. monitor priorities & strategies of key global, regional & national stakeholders on infectious diseases in SSA			*not tracked with KPI, but action to be described in AARs*					

op1. **new knowledge** on new/ improved health technologies for the management of infectious diseases in SSA is **produced & communicated to the public & to relevant stakeholders**	i26	**# new/ improved medical interventions that progressed through clinical development due to the JU support and for which evidence on safety, efficacy, or usability was generated by a JU-funded project, with description**	**"New"** = interventions that did not previously exist **"Improved"** = existing interventions that have been modified to enhance efficacy, safety, usability, accessibility, affordability **"Progressed in clinical development"** = completing a certain Phase; advancing to a next Phase	• type of progression (progression from one clinical stage to another and which one/ reported TRL levels) • type of intervention (newly developed or improved) • disease, technology, target groups	EDCTP-specific	moderate	yearly	• Sygma (periodic project reports, final reports) • data from EDCTP Association on projects funded under EDCTP1 & EDCTP2 • Corda - progression through TRL levels as reported in periodic reports • data to be compiled based on dedicated template
	i27	**# new/ improved medical interventions for which evidence on safety, efficacy, or usability was generated by a JU-funded project, with description**		• type of intervention (newly developed or improved) • disease, technology, target groups • type of study results per component (negative, positive)	EDCTP-specific	moderate	yearly	• Sygma (periodic project reports, final reports) • data from EDCTP Association on projects funded under EDCTP1 & EDCTP2 • Corda - progression through TRL levels as reported in periodic reports • data to be compiled based on dedicated template
	i28	**# medical interventions for which evidence on effectiveness, feasibility, acceptability, or scalability was generated through JU-funded implementation research, with description**		• type of intervention (newly developed or improved) • disease, technology, target groups • type of study results per component (negative, positive)	EDCTP-specific	moderate	yearly	• Sygma (periodic project reports, final reports) • data from EDCTP Association on projects funded under EDCTP1 & EDCTP2 • Corda - progression through TRL levels as reported in periodic reports • data to be compiled based on dedicated template
	i29	**# research datasets or databases established, maintained, or made accessible through JU-funded projects, with description**		• by type (trial databases; surveillance databases, etc) • by access level (public, restricted-to whom)	EDCTP-specific	moderate	yearly	• Sygma (periodic project reports, final reports) • data from EDCTP Association on projects funded under EDCTP1 & EDCTP2 • Corda - progression through TRL levels as reported in periodic reports • data to be compiled based on dedicated template
	i30	**# and % of results in specific Horizon Europe R&I missions**	# and % results under the KIPs 1, 2, 3, 7 and 9 short-term indicators for each identified mission will be measured by Horizon Europe team		Horizon Europe KIP 5.1	low	yearly	• Sygma continuous and periodic reports by grantees • data provided by Horizon Europe team upon request, will be also included in HE dashboard
	i31	**# and % results aimed at addressing identified Union policy priorities and global challenges (including SDG), & including climate-relevant results aimed at delivering on the Union's commitment under the Paris Agreement**	combination of data for KIPs 3.1, 7.1, and 9.1 will be measured by Horizon Europe team	• EU policy priority, including delivering on the Union's commitment under the Paris Agreement • UN SDGs • type of output (as per KIPs 1-3 and 7-9) • type of Horizon Europe action • programme year • type of participating organisations • country	Horizon Europe KIP 4.1	low	yearly	• Sygma continuous and periodic reports by grantees • Sygma data on policy monitoring indicators • data provided by Horizon Europe team upon request, will be also included in HE dashboard
	i32	**# peer-reviewed scientific publications resulting from the Programme**	number of matched and validated Horizon Europe-funded publications published primarily in peer-reviewed journals and conference proceedings will be measured by Horizon Europe team	• types of publication (journal article/ publication in conference proceedings, workshop/ monograph/ book chapter/ thesis, dissertation/ other) • type of Horizon Europe action • programme year • type of participating organisation • country of participating organisation • field of science (where possible)	Horizon Europe KIP 1.1	low	yearly	• Sygma continuous and periodic reports by grantees • data provided by Horizon Europe team upon request, will be also included in HE dashboard
	i33	**# innovative products, processes, methods resulting from the Programme, and intellectual property rights (IPR) applications**	will be measured by Horizon Europe team	• type of Horizon Europe action • programme year • type of participating organisations • country of participating organisation	Horizon Europe KIP 7.1	low	yearly	• Sygma continuous and periodic reports by grantees • data provided by Horizon Europe team upon request, will be also included in HE dashboard
	i34	**% research outputs (open data/publication/software etc.) resulting from the Programme shared through open knowledge infrastructures**	will be measured by Horizon Europe team	• type of output (publication / dataset / software) • type of scientific publication • type of Horizon Europe action • programme year • type of participating organisations • country • licence type • embargo period used • field of science (where possible)	Horizon Europe KIP 3.1	low	yearly	• Sygma continuous and periodic reports by grantees • data provided by Horizon Europe team upon request, will be also included in HE dashboard

Objective	ID	Indicator	Definition	Breakdown	Type	Priority	Frequency	Data source
op2. exploitation of new/ improved technologies is **planned** under reasonable conditions or non-exclusive licenses, with due attention to market exploration & IP when relevant	i35	**% Global Access Plans with high scores on planned availability & accessibility**	proportion of submitted Global Access Plans that score highly on the availability/accessibility-related criteria within the Scoring Matrix		EDCTP-specific	high	yearly	• Global Access Plans assessment scoring matrix
op3. stakeholders and communities in participating countries, incl. industry & SMEs, are **appropriately engaged** in all stages of the JU-supported projects	i36	**# and % projects funded by the Programme where [Union] citizens and end-users contribute to the co-creation of R&I content**	count of all ongoing and completed Horizon Europe projects in which citizens and end-users contribute to the co-creation of R&I content will be measured by Horizon Europe team	• citizens, end-users • type of Horizon Europe action • programme year • type of participating organisations • country of participating organisations	Horizon Europe KIP 6.1	low	yearly	• Sygma continuous and periodic reports by grantees • data provided by Horizon Europe team upon request, will be also included in HE dashboard
	i37	**# and % participating legal entities which have citizens and end user engagement mechanisms in place after the end of projects funded by Programme**	will be measured by Horizon Europe team	• mechanism of engagement • type of participating organisations; • country of participating organisations	Horizon Europe KIP 6.2	low	yearly	• Sygma continuous and periodic reports by grantees • data provided by Horizon Europe team upon request, will be also included in HE dashboard
op4. enhanced institutional & technical capacity of organisations involved in the JU-supported projects to tackle infectious diseases, incl. upgraded laboratories & clinical facilities	i38	**# countries & institutions participating in Global Health EDCTP3-supported projects that address epidemic preparedness**		• region	EDCTP-specific	low	quarterly	• Corda • Census based- internal spreadsheet for grants' categorisation by disease, technology, research type, trial phase, target groups
	i39	**# laboratories and clinical facilities upgraded with the direct contribution of a Global Health EDCTP3-funded project**		• country & world region • project & project type • facility type • upgrade type • accreditation status (incl upgraded but not accredited, vs upgraded and newly accredited, vs upgraded and existing accreditation maintained)	EDCTP-specific	moderate	yearly	• Sygma (periodic project reports, final reports) • data from EDCTP Association on projects funded under EDCTP1 & EDCTP2 • data to be compiled based on dedicated template
	i40	**# full time equivalent (FTE) jobs created, and jobs maintained in participating legal entities for the projects funded by the Programme**	will be measured by Horizon Europe team	• type of Horizon Europe action • programme year • type of participating organisations • country of participating organisations	Horizon Europe KIP 8.1	low	yearly	• Sygma continuous and periodic reports by grantees • data provided by Horizon Europe team upon request, will be also included in HE dashboard
op5. set/ strengthened functional ethics & regulatory frameworks in project countries, based on international standards for GCP	i41	**# countries with newly established or revised ethics and/or regulatory frameworks with the direct contribution of a Global Health EDCTP3-funded project**		• type of framework • type of aspects strengthened	EDCTP-specific	moderate	yearly	• Sygma (periodic project reports, final reports) • Post-project reports • data from EDCTP Association on projects funded under EDCTP1 & EDCTP2 • data to be compiled based on dedicated template
	i42	**# regional-level ethics and regulatory frameworks developed or revised with the EDCTP contribution, with description**	EDCTP contribution = contribution of EDCTP Association and/or Global Health EDCTP3	• type of framework • type of aspects strengthened	EDCTP-specific	moderate	yearly	• Sygma (periodic project reports, final reports) • data from EDCTP Association on projects funded under EDCTP1 & EDCTP2 • data to be compiled based on dedicated template
	i43	**# ethics or regulatory committees established with JU support that remain active two years after the JU support ends**		• country • regional representation	EDCTP-specific	moderate	yearly	• data from EDCTP Association on projects funded under EDCTP1 & EDCTP2 • data to be compiled based on dedicated template • info available in the public domain (eg. activity reports of said committees)
op6. individuals in SSA, including underrepresented groups, develop experience & complete **training, mentoring & coaching** in clinical research implementation, oversight & governance	i44	**# researchers who receive(d) Global Health EDCTP3-funded fellowship/ research/ training grants**		• country/ world region • specialisation area • type (fellowship, studies - mentioning degree, traineeship, etc) • gender • career stage • completion status (of respective EDCTP-funded fellowship training, studies, etc)	EDCTP-specific	moderate	every six months	• data to be requested from grantees • data to be compiled based on dedicated template
	i45	**# staff involved in the implementation of JU-funded projects**		• gender • position type; in leading roles/team members • country • type of project	EC Reporting Requirements	low	every six months	• Sygma continuous and periodic reports by grantees • extractable from Corda
	i46	**# researchers involved in upskilling (training, mentoring/coaching, mobility and access to R&I infrastructures) activities in projects funded by the Programme**	based on the list of project participants (project team) will be measured by Horizon Europe team	• career stage • type of Horizon Europe action • programme year • type of participating organisations • country of participating organisations • field of science (where possible) • gender	Horizon Europe KIP 2.1	low	yearly	• Sygma continuous and periodic reports by grantees • data provided by Horizon Europe team upon request, will be also included in HE dashboard

Objective	ID	Indicator	Definition	Breakdown	Category	Priority	Frequency	Data source
op7. increased visibility of the JU & its strategic priorities among relevant stakeholders in global health research & policy	i47	# known mentions of EDCTP in media sources, research publications, and policy documents at the global, regional, and national level	known # times EDCTP is mentioned in media sources, research publications, and policy documents at the global, regional, and national level, with specification of source/mention, other than mentions by EDCTP or the JU themselves	• source type	EDCTP-specific	high	yearly	• internal records • data to be compiled based on dedicated template
	i48	international visibility level of EDCTP	Visibility of the partnership in national, European, international policy/industry cycles		shared across JUs KPI 11	moderate	yearly	internal tracker of Global Health EDCTP3 mentions in policy documents & guidelines, studies produced by third parties
op8. broadened & more inclusive engagement of **countries** & **strategic actors** in the JU governance, joint calls & policy-level initiatives	i49	# entities with which Global Health EDCTP3 has formal collaboration agreements		• purpose of collaboration • type of collaboration • geographic scope of collaborating entity/ies • sector of entity/ies	EC Reporting Requirements	moderate	yearly	• internal partnerships records (MoUs, letters of endorsements, etc) • data to be compiled based on dedicated template
	i50	existence of tangible collaboration with the Neighbourhood, Development, and International Cooperation Instrument	yes/no + description		EC Reporting Requirements	moderate	yearly	internal partnerships records (MoUs, letters of endorsements, etc)
	i51	# international actors involved	• # and types of organisations and countries most represented in the partnership (members) • evolution of memberships of countries and associations (no. and types of activities, cash and in-kind contributions)	• type of organisation • type of contribution • type of activities	shared across JUs KPI 4	moderate	yearly	• internal partnerships records (MoUs, letters of endorsements, etc) • data to be compiled based on dedicated template
	i52	share & type of stakeholders and countries invited/engaged	share & type of stakeholders and countries invited/engaged in: Governance structures; SRIA development and call topics; Call implementation and other activity involvement.	• type of stakeholders • country	shared across JUs KPI 5	moderate	yearly	• internal records on GB membership & meetings • internal records on contributions of advisory bodies to SRIA, ARIAs, and annual work programmes
	i53	# and types of newcomer partners in partnerships and countries of origin (geographical coverage)	newcomer partners in partnerships = organisations that have never been included in any types of European R&I partnerships before.	• type of partners • country	shared across JUs KPI 6	moderate	yearly	• internal partnerships records (MoUs, letters of endorsements, etc) • data to be compiled based on dedicated template
	i54	# and type of coordinated and joint activities with other European Partnerships	description of e.g., joint calls, trainings, sharing infrastructure, involvement in governance structures, etc.	• type of activity • partnership	shared across JUs KPI 8	moderate	yearly	• internal partnerships records (MoUs, letters of endorsements, etc) • data to be compiled based on dedicated template
	i55	# and type of coordinated and joint activities with other R&I Initiatives at EU/national/regional/sectorial level	description of e.g., consequent calls in national programmes, capacity building or upscaling/ exploitation actions at national / regional / sectorial level, etc	• type of activity • initiative • level of the initiative (EU/regional/national/sectorial)	shared across JUs KPI 9	moderate	yearly	• internal partnerships records (MoUs, letters of endorsements, etc) • data to be compiled based on dedicated template
	i56	# members participating in EDCTP governance bodies		• governance body • new/ongoing • gender • country and/or world region	EC Reporting Requirements	low	yearly	• internal records on governance and advisory bodies • JU website
op9. increased co-funding mobilized by the JU from external stakeholders for research & capacity development on infectious diseases	i57	amounts and % from total of public investments by EDCTP Association participating states in actions contributing to Global Health EDCTP3 objectives		• country & world region • type of investment (cash, in-kind) • area of investment	EC Reporting Requirements	moderate	yearly	• internal financial records • IKAA reports
	i58	financial (€) and in-kind contributions, committed and actual [direct leverage]	• How much public funding (€) was generated for 1 € of EU contribution? • How much private funding (€) was generated for 1 € of EU contribution? • How much in-kind contributions generated by 1 € of EU contribution?	• public/private • country • type of contribution (IKAA, IKOP, Financial Contribution, other eligible contributions by consortium participating entities)	shared across JUs KPI 1	moderate	yearly	• internal financial records • IKAA reports • data to be compiled based on dedicated template
	i59	overall (public and private, in-kind and cash) /additional investments mobilised towards EU priorities	differentiation of contributions to specific areas (e.g., clusters, other crosscutting objectives, Union priorities or SDGs). How much overall/additional investment is generated by European Partnerships for specific areas (Example: x% directed to carbon emissions reduction)?	• priority area/ SDG	shared across JUs KPI 3	moderate	yearly	• Sygma/ Corda data on policy monitoring indicators • IKAA reports
	i60	complementary and cumulative funding from other Union funds (Horizon Europe Europe, National funding, ERDF, RRF, Other cohesion policy funds, CEF, DEP)		• Union fund	shared across JUs KPI 10	moderate	yearly	internal partnerships records (MoUs, letters of endorsements, etc)
	i61	amount of public and private investment mobilised with the initial investment from the Programme	The difference between the total and the EU funding will be measured by Horizon Europe team	• type of Horizon Europe action • programme year • type of participating organisations • country of participating organisations	Horizon Europe KIP 9.1	low	yearly	• Corda
	i62	# experts contributing to grant proposals evaluations		• gender • sector (incl CSOs, private sector) • country of primary citizenship (+ north/south) • new/renewed	EC Reporting Requirements	low	yearly	• Horizon Europe dashboard (EC-built) • Corda • SEP

	ID	Indicator	Definition	Disaggregation	Alignment	Complexity	Frequency	Data source
op10. increased & more inclusive collaboration among SSA & European organisations, researchers, industry, SMEs, investors & external experts engaged in the JU-supported projects & processes	i63	# and types of newcomer organisations in JU-funded projects (in terms of types and countries of origin)	newcomer project beneficiaries = organisations that have never participated in a project supported by any partnerships before (could be part of Horizon Europe Europe/H2020, though).	• type of organisation • country of origin • role in the project (associate/partner/Coordinator)	shared across JUs KPI 7	low	yearly	• Corda • data from EDCTP Association
	i64	# and % JU-funded projects with coordinator and/or scientific leader an insititution in SSA	**numerator:** # EDCTP-funded projects in which a SSA institution has the role of project coordinator or scientific project lead **denominator:** total # EDCTP-funded projects	• type of coordintion (scientific or project) • project type • country	EDCTP-specific	moderate	quarterly	• Corda • requires manual processing
	i65	# and % JU-funded projects with industry and/or private foundations participation	**numerator:** # EDCTP-funded projects with at least one industry and/or private foundation organisation among participating entities **denominator:** total # EDCTP-funded projects	• type of project • disease & technology • country & world region	EDCTP-specific	moderate	quarterly	• data available in Corda
	i66	# new or strengthened regional networks of excellence sharing good practice, extending capacity, and creating platforms for multicentre trials, supported by the JU or by the EDCTP Association		• country/world region of participants	EDCTP-specific	moderate	yearly	• reports from EDCTP Association • Sygma periodic reports from network grants • data to be compiled based on dedicated template
	i67	# members in the regional networks of excellence supported by the JU or by the EDCTP Association		• network/hub • type of member/ user (institutional, individual, country)	EDCTP-specific	moderate	yearly	• reports from EDCTP Association • Sygma periodic reports from network grants • data to be compiled based on dedicated template
	i68	# and % active users of JU's b2match networking platform who participated in project proposals for JU funding in partnership with other b2match users with whom they had meetings through the platform	active - who had at least one meeting within the platform with another user **denominator:** all active users of the platform	• new/renewal status of the organisation represented • country • sector of the organisation • application selection status	EDCTP-specific	moderate	yearly	• b2match platform data • Corda data
	i69	# and % peer-reviewed publications co-authored by private-public stakeholders	% out of total publications produced as part of Global health EDCTP3-funded projects		EDCTP-specific	high	yearly	• Corda - list of publications • tbc: bibliometric analysis by Horizon Europe
	i70	# and % peer-reviewed publications co-authored by African and European researchers who were involved in EDCTP-funded actions	% out of total publications produced as part of Global health EDCTP3-funded projects		EDCTP-specific	high	yearly	• Corda - list of publications • tbc: bibliometric analysis by Horizon Europe
	i71	Programme beneficiaries who have developed new transdisciplinary/ trans-sectoral collaborations with users of their open-access research outputs that have resulted from the Programme	will be measured by Horizon Europe team	• type of OA output (publication / dataset / software) • programme year • country • feld of science (where possible)	Horizon Europe KIP 3.3	dedicated study	twice during the Programme, starting 2025/2026	dedicated study by EC

OUTCOMES (IMMEDIATE/ INTERMEDIATE)

	ID	Indicator	Definition	Disaggregation	Alignment	Complexity	Frequency	Data source
oc6. the new knowledge created through EDCTP grants **advances the medical field & clinical practice** for tackling infectious diseases	i72	Citation index of peer-reviewed publications resulting from the Programme	mean normalised citation score (MNCS) = number of citations actually received by publications / number of citations expected for a publication in the same publication year and subject field will be measured by Horizon Europe team	• type of Horizon Europe action • programme year • type of participating organisation • country of participating organisation • field of science (where possible)	Horizon Europe KIP 1.2	low	yearly	bibliometric analysis, Scopus
	i73	# and % citations of open-access research outputs, and field-weighted share of OA publications resulting from the Programme	will be measured by Horizon Europe team	• type of output (publication / dataset / software) • programme year • country • field of science (where possible)	Horizon Europe KIP 3.2	low	yearly	bibliometric analysis, OpenAire
	i74	# and % peer reviewed publications resulting from projects funded by the Programme that are core contributions to scientific fields	percentage of the top-cited publications (PPTop 1% - PPTop 50%) will be measured by Horizon Europe team	• type of Horizon Europe action • programme year • type of participating organisation • country of participating organisation • field of science (where possible)	Horizon Europe KIP 1.3	low	yearly	bibliometric analysis, Scopus
oc7. new/ improved technologies are approved for use & included in relevant protocols, policies & guidelines	i75	**# medical products resulting from EDCTP-funded projects pre-qualified by WHO recommendations and/or that received regulatory approval to be marketed, with description**	Products that have received WHO Prequalification (PQ) status following WHO's official evaluation process, OR that have been recommended by WHO expert committees. Products that received regulatory aproval to be marketed by a Stringent Regulatory Authority as per WHO's SRA list (EMA, FDA, etc), or by a National Regulatory Authority.	• type of product (eg., new; in use but improved; new combination for a specific target population, etc) • disease, technology, research type, trial phase, target groups • authority providing (pre-)aproval (international regulatory authority; member state National Regulatory Authority; WHO recommendations)	EDCTP-specific	high	everytime such an output happens	• TRL levels reported in periodic and final reports (TRL levels 8-->9) • post-grant annual reports by grantees • data from EDCTP Association • for specific products: outputs of EDCTP3 grants (funded acceptability studies/ implementation research)
	i76	# new or changed guidelines and/or policies for improved or extended use of existing medical interventions resulting from EDCTP-funded projects and actions, with description		• disease, technology, research type, trial phase, target groups • type of changed/improved guidelines/ policies • country / world region	EDCTP-specific	high	everytime such an output happens	• post-grant annual reports by grantees • JU internal reports • EDCTP Association data

Outcome	ID	Indicator	Notes/Definition	Disaggregation	Source	Priority	Frequency	Data source
	i77	# innovations resulting from projects funded by the Programme, including from awarded Intellectual Property Rights (IPRs)	will be measured by Horizon Europe team	• type of innovation • type of Horizon Europe action • programme year • type of participating organisations • country of participating organisations	Horizon Europe KIP 7.2	low	yearly	administrative and monitoring data submitted by HE participants; PATSTAT
oc8. new/ improved technologies are available, affordable, known & accepted for use by intended end beneficiaries	i78	# new/improved medical products known to be available for use by end beneficiaries, with description		tbd	EDCTP-specific	high	yearly after project end	• post-grant annual reports by grantees • for specific products: outputs of EDCTP3 grants (funded acceptability studies/ implementation research)
oc9. strengthened clinical research institutions in SSA, with improved equipment, job opportunities, internal processes, & market share	i79	# and % EDCTP-supported researchers whose working conditions improved after their participation in EDCTP-supported initiatives		• country / world region • gender • field of science • career stage • type of envolvement in EDCTP-funded projects	EDCTP-specific	high	at end of Programme	• tracer study - online survey with former EDCTP fellows and project participants - same as for OC11
	i80	# and % of Global Health EDCTP3-supported laboratories and clinical sites demonstrating improvements in diagnostic capacity by the end of project completion	improvement = increased testing ; reduced testing time; expanded diagnostic portfolio	• country • accreditation status (maintained existing accreditation; achieved new accreditation; no acccreditation) • whether support also in EDCTP2 and/or EDCTP1	EDCTP-specific	high	yearly after project end	• end of project reports • post-grant reports
	i81	# and % upskilled researchers involved in the Programme with improved working conditions, including researchers' salaries	will be measured by Horizon Europe team	• country • career stage • field of science (where possible) • gender • aspects of working conditions (salary, employment contract type, social security provisions)	Horizon Europe KIP 2.3	low	every 2 years	Horizon Europe has a survey (MORE) to collect data on researchers' net salaries and working conditions across Europe
	i82	creation, growth and market shares of companies having developed innovations in the Programme	will be measured by Horizon Europe team		Horizon Europe KIP 7.3	low	twice during the Programme	administrative and monitoring data submitted by HE participants; Orbis; NEMESIS/QUESTIII/RHOMOLO econometric models
	i83	increase of FTE jobs in participating legal entities following the project funded by the Programme	# jobs/FTEs expected to remain or be created following FP funding will be measured by Horizon Europe team	• type of job (researcher / technician / administrative support and project management / other) • type of Horizon Europe action • programme year • type of participating organisations • country of participating organisations	Horizon Europe KIP 8.2	low	twice during the Programme	administrative and monitoring data submitted by HE participants; Orbis
	i84	# direct & indirect jobs created or maintained due to diffusion of results from the Programme	will be measured by Horizon Europe team	• types of jobs by skill level (low/ medium/ high skills) • sector (NACE) • country (EU MSs)	Horizon Europe KIP 8.3	low	twice during the Programme	administrative and monitoring data submitted by HE participants; NEMESIS
oc10. increased maturity of national regulatory & ethics systems for health product development, enabling sustainable oversight beyond the JU support	i85	# and % countries that received EDCTP support for strengthening their regulatory frameworks that attained regulatory systems maturity level 3 or higher on the WHO benchmarking scale	Maturity Level 3 indicates that the system is well-functioning and regulatory decisions are sustained and aligned with international standards	• type of support provided • EDCTP iteration in which support provided	EDCTP-specific	moderate	at baseline at end of Programme	The World Health Organization's (WHO) Global Benchmarking Tool (GBT) WHO assessments or national benchmarking reports, annual reports (list of countries only where maturity level is 3 or 4)
	i86	# and % countries that received EDCTP support for strengthening their ethics and/ or regulatory frameworks with evidence of sustained operations (e.g., routine inspections, enforcement, policy updates) of respective frameworks	Systems show evidence of consistent functionality, such as annual audits, follow-up inspections, or issuance of guidelines desk review; use of a scoring system with rubrics	• type of support provided • EDCTP iteration in which support provided	EDCTP-specific	high	at baseline at end of Programme	National regulatory authority (NRA) and ethics committee reports where publicly available info likely fragmented
	i87	average time (#days) taken by national regulatory authorities (NRAs), Ethics Review Committees (ERCs), and/or other regulatory bodies to approve clinical research / clinical trial protocols in countries that received EDCTP support for strengthening regulatory/ ethics review frameworks	other regulatory bodies = Ministry of Health ; National Medicines Regulatory Authorities ; Biosafety Committees ; Data and Safety Monitoring Boards	• type of support provided • EDCTP iteration in which support provided	EDCTP-specific	high	at baseline at end of Programme	Possible sources: NRA (National Regulatory Authority), ERC (Ethics Review Committee), AVAREF (African Vaccine Regulatory Forum) public reports; EDCTP grantee reports; WHO Global Observatory on Health R&D info likley fragmented
	i88	# and % countries that received EDCTP support for strengthening their ethics systems with national ethics committees having achieved international accreditation		• type of support provided by the JU • EDCTP iteration in which support provided	EDCTP-specific	moderate	at baseline at end of Programme	Accreditation by recognised bodies such as SIDCER (Strategic Initiative for Developing Capacity in Ethical Review), WHO, African Medicine Agency, AVAREF (African Vaccine Regulatory Forum), etc
	i89	# and % researchers involved in EDCTP grants who continued working in respective fields after the EDCTP project		• career progression category • gender • country/ world region • time since researcher received EDCTP support • type of support provided • EDCTP iteration in which support provided	EDCTP-specific	high	at end of Programme	tracer study - online survey with former EDCTP fellows and project participants

	ID	Indicator	Definition	Disaggregation	Framework	Priority	Timing	Data source
oc11. upskilled individuals become **more effective** in producing and disseminating **knowledge & practice** on tackling infectious diseases in SSA	i90	**# and % researchers involved in EDCTP grants who continued working in same geograhic area (country, region) after the EDCTP project**		• career progression category • gender • country/ world region • time since researcher received EDCTP support • type of support provided • EDCTP iteration in which support provided	EDCTP-specific	high	at end of Programme	tracer study - online survey with former EDCTP fellows and project participants
	i91	**# and % researchers involved in EDCTP grants who joined implementation teams in other research initiatives addressing infectious diseases in SSA after receiving EDCTP support**		• career progression category • gender • country/ world region • time since researcher received EDCTP support • type of support provided • EDCTP iteration in which support provided	EDCTP-specific	high	at end of Programme	tracer study - online survey with former EDCTP fellows and project participants
	i92	**# and % researchers previously involved in EDCTP grants who contributed/ authored research publications, reports, guidelines or policies in an area linked to tackling infectious diseases in SSA**		• career progression category • gender • country/ world region • time since researcher received EDCTP support • type of support provided • EDCTP iteration in which support provided	EDCTP-specific	high	at end of Programme	tracer study - online survey with former EDCTP fellows and project participants
	i93	**% researchers who perceive EDCTP support as significant contributor to their career progression in the field of infectious diseases in SSA**		• career progression category • gender • country/ world region • time since researcher received EDCTP support • type of support provided • EDCTP iteration in which support provided	EDCTP-specific	high	at end of Programme	tracer study - online survey with former EDCTP fellows and project participants
	i94	**# and % upskilled researchers involved in the Programme with increased individual impact in their R&I field (increased H-index)**	H-index = comparison of the number of articles written by an author to the number of citations will be measured by Horizon Europe team	• country • gender • career stage • field of science (where possible)	Horizon Europe KIP 2.2	low	yearly	grantees' reports combined with external bibliometric analysis tools (Scopus database)
oc12. better alignment across Europe & Africa **on a global health research agenda** & better coordinated regional & national research programs on infectious diseases	i95	**most significant examples of synergies between Global Health EDCTP3 actions and global, regional, national relevant initiatives and policies**	qualitative indicator - narrative	• geographic scope • country/ region • type	EC Reporting Requirements	moderate	yearly	internal records on partnerships
	i96	**EDCTP Association participating states' budget in centrally funded activities and in joint activities with other participating States**			EDCTP-specific	moderate	yearly	IKAA reports
	i97	**amounts and % allocated budget from total state budget for public health/ infectious diseases**		• country • disease, technology	EDCTP-specific	moderate	at baseline at end of Programme	Gfinder data at country level
oc13. better aligned regulatory mechanisms among SSA countries & **increased common regulatory reviews** in SSA region for new health products	i98	**# of SSA countries or regulatory authorities participating in shared review processes, harmonized frameworks, or mutual reliance mechanisms for clinical trials or health product approvals**		• type	EDCTP-specific	moderate	at baseline at end of Programme	documents from national level reports or regional initiatives (African Medicines Regulatory Harmonization AMRH, African Vaccine Regulatory Forum AVAREF; Africa Medicines Agency AMA; ZaZiBoNa initiative)
oc14. increased co-funding & **joint activities across sectors** to develop, exploit or scale up EDCTP-supported new/ improved health technologies	i99	**additional investments triggered by the EU contribution, notably for exploiting or scaling up results (linked to but outside the partnerships, including qualitative impacts and success stories) [indirect leverage]**	additional activities or investments triggered by the partnership (not as part of the partnership but in addition to it). Partnership acts as a kind of a trigger (e.g., because of a partnership, MS decides to launch a national programme). These can include e.g. private investments in training or activities required for putting on the market the product/service which results from the European Partnership; or public investments mobilised from other EU/ national / regional programmes (e.g. ERDF, CEF)	• country • purpose of investment • source of investment	shared across JUs KPI 2	moderate	yearly after project end	post-grant annual reports
	i100	**amount of public and private investment mobilised to exploit or scale up results from the Programme (including foreign direct investments)**	will be measured by Horizon Europe team	• type of Horizon Europe action • programme year • type of participating organisations • country of participating organisations	Horizon Europe KIP 9.2	low	yearly	administrative and monitoring data submitted by HE participants; Orbis, Zephyr, Dealroom and Crunchbase

OUTCOMES (LONG-TERM)

	ID	Indicator	Definition	Disaggregation	Framework	Priority	Timing	Data source
oc1. new/ improved technologies are used for diagnosing, treating & preventing infectious diseases in SSA	i101	**# of new/ improved technologies that became integrated into healthcare services, national healthcare programmes, or disease-specific initiatives, with description**		tbd	EDCTP-specific	high	yearly after project end	• post-grant annual reports by grantees • desktop research conducted/commissioned by JU
	i102	**# intended end beneficiaries known to have used the technology in the past year**		tbd	EDCTP-specific	high	yearly after project end	• post-grant annual reports by grantees • desktop research conducted/commissioned by JU

Category	ID	Indicator	Methodology / Notes	Disaggregation	Source type	Rating	Frequency	Data sources
	i103	uptake and outreach of co-created scientific results and innovative solutions generated under the Programme	will be measured by Horizon Europe team		Horizon Europe KIP 6.3	dedicated study	twice during the Programme	data from long-term indicators for KIPs 1, 3, 4 and 7
oc2.strengthened R&I capacities & national health systems in SSA for tackling infectious diseases	i104	**# peer-reviewed publications and patents originating from SSA institutions tackling infectious diseases**	combination between bibliometric analysis and patent searches desktop research	tbd	EDCTP-specific	high	at baseline at end of Programme	Scopus, PubMed, national patent databases
	i105	**average NHRS (National Health Research Systems) Barometer Score for SSA countries that participated in EDCTP-supported projects**	desktop research	• country • key dimensions (governance, financing, research production, research use)	EDCTP-specific	moderate	at baseline at end of Programme	NHRS assessment reports (WHO-Afro)
	i106	**# new clinical trials conducted with the involvment of participating entities in SSA, as reported in public clinical trials registry platforms**	desktop research	tbd	EDCTP-specific	moderate	at baseline at end of Programme	clinical trials registry platforms (PACTR - Pan African Clinical Trials Registry; ICTRP - International Clinical Trials Registry Platform) periodic reports from CTCAN project
oc3. improved capacity of SSA institutions to detect & diagnose **emerging diseases** of epidemic potential	i107	**# diagnostic laboratories in countries that received EDCTP support for capacity strengthening that achieved and maintained international accreditation for infectious disease diagnostics**	desktop research	• country	EDCTP-specific	high	at baseline at end of Programme	Accreditation bodies (e.g., WHO, ISO - list to be expanded)
	i108	**WHO JEE scores - SSA countries' capacity level to prevent, detect, and respond to health emergencies**	Score 1–2 = low or limited capacity Score 3 = developed capacity Score 4–5 = demonstrated or sustainable capacity	• country • domain (prevent, detect, respond, and other IHR-related hazards)	EDCTP-specific	moderate	at baseline at end of Programme	JEE score (Joint External Evaluation) of the WHO's International Health Regulations (IHR 2005) https://www.who.int/health-topics/international-health-regulations#tab=tab_1
	i109	**time taken to detect and confirm an outbreak of an emerging disease**	desktop research	• time thresholds (below 72h; 72h-120h; 120h-168h; above 168h) • by country	EDCTP-specific	high	at baseline at end of Programme	WHO outbreak reports (WHO/AFRO), national disease surveillance systems reports
oc4. improved efficiency & effectiveness of public & private investments in combatting infectious diseases in SSA	i110	**amount of public and private investment for tackling infectious diseases incl. through clinical research, covering regions and disease areas under EDCTP, as reported in public grant portals and trackers**	desktop research	• source • purpose	EDCTP-specific	high	at baseline at end of Programme	Gfinder, other funding trackers
oc5. strengthened North-North, North-South & South-South partnerships in global health research among private & public sector organisations	i111	**# of new or expanded co-funded activities takling infectious diseases among EDCTP3 beneficiary states & EU countries**	desktop research		EDCTP-specific	high	at baseline at end of Programme	publicly available reports
	i112	**# of new or expanded cross-regional partnerships (North-North, North-South, South-South) established to address infectious diseases in SSA**	desktop research	tbd	EDCTP-specific	high	at end of Programme	publicly available reports

IMPACT

Category	ID	Indicator	Methodology / Notes	Disaggregation	Source type	Rating	Frequency	Data sources
Im1. reduced socio-economic burden of infectious diseases in SSA	i113	**prevalence rates of relevant infectious diseases in relevant populations of SSA**	'relevant' = that were within the scope of EDCTP-funded projects or EDCTP actions	tbd	EDCTP-specific	moderate	at baseline at end of Programme	public reports on key health outcomes (governments, WHO, global funds, WB, etc)
	i114	**DALY (disability-adjusted life years; total years of healthy life lost due to illness, disability, or premature death) for relevant infectious diseases in relevant populations of SSA**	'relevant' = that were within the scope of EDCTP-funded projects or EDCTP actions	tbd	EDCTP-specific	moderate	at baseline at end of Programme	Institute for Health Metrics and Evaluation (IHME) – Global Burden of Disease (GBD) Study World Health Organization (WHO) – Global Health Estimates (GHE) Africa CDC (Africa Centres for Disease Control and Prevention)

	i115	mortality & morbidity rates of relevant infectious diseases in the populations of SSA	'relevant' = that were within the scope of EDCTP-funded projects or EDCTP actions	tbd		EDCTP-specific	moderate	at baseline at end of Programme	public reports on key health outcomes (governments, WHO, global funds, WB, etc)
Im2. increased health security in SSA & globally, including with regards to AMR & effects of climate change	i116	AMR prevalence in high-priority Pathogens	% clinical samples showing resistance to key antimicrobials in priority pathogens	tbd		EDCTP-specific	moderate	at baseline at end of Programme	WHO Global Antimicrobial Resistance and Use Surveillance System (**GLASS**), which provides data on AMR prevalence across countries.
	i117	incidence rates of infectious diseases in the population of SSA, including # instances where a country eliminates an infectious disease (as per WHO criteria)		tbd		EDCTP-specific	moderate	at baseline at end of Programme	public reports on key health outcomes (governments, WHO, global funds, WB, etc)
	i118	International Health Regulations (IHR) Core Capacity Score - *IHR scores related to detection, response, and health system resilience.*	HR Core Capacity Score is a metric used to assess a country's ability to detect, assess, notify, and respond to public health threats, as outlined in the WHO International Health Regulations (IHR, 2005). It is measured across 13 core capacities, with a focus on detection, response, and health system resilience. **1-100%**	• country • Score sub-domain		EDCTP-specific	moderate	at baseline at end of Programme	WHO's annual International Health Regulations (IHR) State Party Self-Assessment Annual Reporting (SPAR) database
	i119	vaccination coverage for key infectious diseases		tbd		EDCTP-specific	moderate	at baseline at end of Programme	WHO and UNICEF national immunization coverage estimates
Im3. progress towards SDGs, EU & AU policy priorities	i120	# and % project innovations contributing to EU policy priorities, including SDGs, & including climate-relevant innovations and research outcomes that deliver on the Union's commitment under the Paris Agreement	innovations = new/ improved technologies and instruments will be measured by Horizon Europe team	• UN SDGs • types of innovation (new or significantly improved methods, technologies and instruments / commercial goods / commercial services / scientific or industrial processes / business models) • country	Horizon Europe KIP 4.2	low	yearly	administrative and monitoring data submitted by HE participants
	i121	aggregated estimated effects of the use/exploitation of results funded by the Programme on tackling identified Union policy priorities and global challenges (including SDGs), including their contributions to the policy and law-making cycle	aggregated estimated effects from the use/exploitation of results identified under other KIPs, including their contributions to the policy and law-making cycle will be measured by Horizon Europe team	• UN SDGs	Horizon Europe KIP 4.3	dedicated study	twice during the Programme	classification of outputs and innovation and scientific results under short-term and medium-term indicators, Innovation Radar, SINEQUA-indexed data
	i122	# and % outcomes in specific R&I missions	# and % of outcomes under the KIP 2, 3 and 7 medium-term indicators for each identified mission will be measured by Horizon Europe team		Horizon Europe KIP 5.2	low	yearly	administrative and monitoring data submitted by HE participants
	i123	targets achieved in specific R&I missions	will be measured by Horizon Europe team		Horizon Europe KIP 5.3	dedicated study	twice during the Programme	administrative and monitoring data submitted by HE participants
	i124	European Union progress towards 3 % GDP target due to the Programme	will be measured by Horizon Europe team	• sector (NACE) • country (EU Member States)	Horizon Europe KIP 9.3	dedicated study	twice during the Programme	administrative and monitoring data submitted by HE participants; NEMESIS

#	Core Indicator	disaggregates
i17	# projects selected for funding, with signed Grant Agreements	• call & call topic • participants' newcomer status • participants' type (incl SMEs and PDPs) • disease; technology; research type (including research of cost effectiveness and economic benefits of research products; research on uptake of results into policy and practice); trial phase; target groups (including vulnerable populations groups specified in SRIA) • country • EDCTP iteration • completion status
i18	grant amounts allocated to projects (EUR), committed and actual	• call & call topic • participants' type (incl SMEs and PDPs) • disease; technology; research type (including research of cost effectiveness and economic benefits of research products; research on uptake of results into policy and practice); trial phase; target groups (including vulnerable populations groups specified in SRIA) • country • EDCTP iteration • committed vs actual
i26	# new/ improved medical interventions that progressed through clinical development due to the JU support and for which evidence on safety, efficacy, or usability was generated by a JU-funded project, with description	• type of progression (progression from one clinical stage to another and which one/ reported TRL levels) • type of intervention (newly developed or improved) • disease, technology, target groups
i27	# new/ improved medical interventions for which evidence on safety, efficacy, or usability was generated by a JU-funded project, with description	• type of intervention (newly developed or improved) • disease, technology, target groups • type of study results per component (negative, positive)
i28	# medical interventions for which evidence on effectiveness, feasibility, acceptability, or scalability was generated through JU-funded implementation research, with description	• type of intervention (newly developed or improved) • disease, technology, target groups • type of study results per component (negative, positive)
i29	# research datasets or databases established, maintained, or made accessible through JU-funded projects, with description	• by type (trial databases; surveillance databases, etc) • by access level (public, restricted-to whom)
i39	# laboratories and clinical facilities upgraded with the direct contribution of a Global Health EDCTP3-funded project	• country & world region • project & project type • facility type • upgrade type • accreditation status (incl upgraded but not accredited, vs upgraded and newly accredited, vs upgraded and existing accreditation maintained)

i41	# countries with newly established or revised ethics and/or regulatory frameworks with the direct contribution of a Global Health EDCTP3-funded project	• type of framework • type of aspects strengthened
i44	# researchers who receive(d) Global Health EDCTP3-funded fellowship/ research/ training grants	• country/ world region • specialisation area • type (fellowship, studies - mentioning degree, traineeship, etc) • gender • career stage • completion status (of respective EDCTP-funded fellowship training, studies, etc)
i49	# entities with which Global Health EDCTP3 has formal collaboration agreements	• purpose of collaboration • type of collaboration • geographic scope of collaborating entity/ies • sector of entity/ies
i58	financial (€) and in-kind contributions, committed and actual [direct leverage]	• public/private • country • type of contribution (IKAA, IKOP, Financial Contribution, other eligible contributions by consortium participating entities)
i61	amount of public and private investment mobilised with the initial investment from the Programme	• type of Horizon Europe action • programme year • type of participating organisations • country of participating organisations
i75	# medical products resulting from EDCTP-funded projects pre-qualified by WHO recommendations and/or that received regulatory approval to be marketed, with description	• type of product (eg., new; in use but improved; new combination for a specific target population, etc) • disease, technology, research type, trial phase, target groups • authority providing (pre-)aproval (international regulatory authority; member state National Regulatory Authority; WHO recommendations)
i78	# new/improved medical products known to be available for use by end beneficiaries, with description	tbd
i80	# and % of Global Health EDCTP3-supported laboratories and clinical sites demonstrating improvements in diagnostic capacity by the end of project completion	• country • accreditation status (maintained existing accreditation; achieved new accreditation; no acccreditation) • whether support also in EDCTP2 and/or EDCTP1

i85	# and % countries that received EDCTP support for strengthening their regulatory frameworks that attained regulatory systems maturity level 3 or higher on the WHO benchmarking scale	• type of support provided • EDCTP iteration in which support provided
i88	# and % countries that received EDCTP support for strengthening their ethics systems with national ethics committees having achieved international accreditation	• type of support provided by the JU • EDCTP iteration in which support provided
i91	# and % researchers involved in EDCTP grants who joined implementation teams in other research initiatives addressing infectious diseases in SSA after receiving EDCTP support	• career progression category • gender • country/ world region • time since researcher received EDCTP support • type of support provided • EDCTP iteration in which support provided
i98	# of SSA countries or regulatory authorities participating in shared review processes, harmonized frameworks, or mutual reliance mechanisms for clinical trials or health product approvals	• type
i99	additional investments triggered by the EU contribution, notably for exploiting or scaling up results (linked to but outside the partnerships, including qualitative impacts and success stories) [indirect leverage]	• country • purpose of investment • source of investment
i101	# of new/ improved technologies that became integrated into healthcare services, national healthcare programmes, or disease-specific initiatives, with description	tbd
i114	DALY (disability-adjusted life years; total years of healthy life lost due to illness, disability, or premature death) for relevant infectious diseases in relevant populations of SSA	tbd

Indicators in the Global Health EDCTP3 M&E system - numbers by types				level of difficulty in data collection/ processing (for EDCTP)			
				dedicated studies (EC)	low	moderate	high
1	Horizon Key Impact Pathway indicators/ KIPs	27		5	22	0	0
2	Indicators needed to comply with EC reporting requirements	21		0	15	6	0
3	Shared KPIs with other Joint Undertakings	11		0	1	10	0
1+2+3	total donor-mandated KPIs (either Horizon KIPs or Regulation-related or shared across JUs or combination	59	48%	5	38	16	0
4	total EDCTP-specific indicators	65	52%	0	12	29	24
	TOTAL # INDICATORS	124		5	50	45	24

Level of difficulty data collection (for Global Health EDCTP3)				
#	level	list concerned indicators	# concerned indicators	
0	dedicated studies (EC)	i71, i103, i121, i123, i124	5	4%
1	high	i35, i47, i69, i70, i75, i76, i78, i79, i80, i86, i87, i89, i90, i91, i92, i93, i101, i102, i104, i107, i109, i110, i111, i112	24	19%
2	moderate	i14, i17, i26, i27, i28, i29, i39, i41, i42, i43, i44, i48, i49, i50, i51, i52, i53, i54, i55, i57, i58, i59, i60, i64, i65, i66, i67, i68, i85, i88, i95, i96, i97, i98, i99, i105, i106, i108, i113, i114, i115, i116, i117, i118, i119	45	36%
3	low	i1, i2, i3, i4, i5, i6, i7, i8, i9, i10, i11, i12, i13, i15, i16, i18, i19, i20, i21, i22, i23, i24, i25, i30, i31, i32, i33, i34, i36, i37, i38, i40, i45, i46, i56, i61, i62, i63, i72, i73, i74, i77, i83, i82, i83, i84, i94, i100, i120, i122	50	40%
		total	124	

summary - Horizon Europe KIPs & corresponding place in the Global Health EDCTP3 M&E Framework		
indicator code	data source?	what does it measure in Global Health EDCTP3 programme logic?
Horizon Europe KIP 1.1	Horizon Dashboard	i32
Horizon Europe KIP 1.2	Horizon Dashboard	i72
Horizon Europe KIP 1.3	Horizon Dashboard	i74
Horizon Europe KIP 2.1	Horizon Dashboard	i46
Horizon Europe KIP 2.2	Horizon Dashboard	i94
Horizon Europe KIP 2.3	Horizon Dashboard	i83
Horizon Europe KIP 3.1	Horizon Dashboard	i34
Horizon Europe KIP 3.2	Horizon Dashboard	i73
Horizon Europe KIP 3.3	estimated through RTD dedicated study	i71
Horizon Europe KIP 4.1	Horizon Dashboard	i31
Horizon Europe KIP 4.2	Horizon Dashboard	i120
Horizon Europe KIP 4.3	estimated through RTD dedicated study	i121
Horizon Europe KIP 5.1	Horizon Dashboard	i30
Horizon Europe KIP 5.2	estimated through RTD dedicated study	i122
Horizon Europe KIP 5.3	Horizon Dashboard	i123
Horizon Europe KIP 6.1	Horizon Dashboard	i36
Horizon Europe KIP 6.2	Horizon Dashboard	i37
Horizon Europe KIP 6.3	estimated through RTD dedicated study	i103
Horizon Europe KIP 7.1	Horizon Dashboard	i33
Horizon Europe KIP 7.2	Horizon Dashboard	i77
Horizon Europe KIP 7.3	Horizon Dashboard	i82
Horizon Europe KIP 8.1	Horizon Dashboard	i40
Horizon Europe KIP 8.2	Horizon Dashboard	i83
Horizon Europe KIP 8.3	Horizon Dashboard	i84
Horizon Europe KIP 9.1	Horizon Dashboard	i61
Horizon Europe KIP 9.2	Horizon Dashboard	i100
Horizon Europe KIP 9.3	estimated through RTD dedicated study	i124

summary - JU common KPIs		
evaluation criterion	indicator reference # in JU guideline	what does it measure in Global Health EDCTP3 programme logic?
additionality	shared across JUs KPI 1	i58
additionality	shared across JUs KPI 2	i99
directionality	shared across JUs KPI 3	i59
intl visibility and positioning	shared across JUs KPI 4	i51
tansparency and openness	shared across JUs KPI 5	i52
transparency and openness	shared across JUs KPI 6	i53
transparency and openness	shared across JUs KPI 7	i63
coherence and synergies	shared across JUs KPI 8	i54
coherence and synergies	shared across JUs KPI 9	i55
coherence and synergies	shared across JUs KPI 10	i60
intl visibility and positioning	shared across JUs KPI 11	i48